Hydromorphone Kalceks
Strong opioid analgesic for severe pain — injectable solution for hospital use
Hydromorphone Kalceks is a potent opioid analgesic containing hydromorphone hydrochloride. It is prescribed for the management of severe pain in adults and adolescents over 12 years of age when other analgesics are insufficient. Administered by injection or infusion (intravenously or subcutaneously), it is approximately 5–10 times more potent than morphine on a milligram basis. As a controlled substance, hydromorphone carries significant risks of respiratory depression, dependence, and misuse and must be used under strict medical supervision.
Quick Facts
Key Takeaways
- Hydromorphone Kalceks is a strong opioid approximately 5–10 times more potent than morphine, used exclusively for severe pain under medical supervision.
- It is administered by intravenous or subcutaneous injection/infusion in hospital and clinical settings — it is not a home-use oral medication.
- The most serious risk is respiratory depression (dangerously slow breathing), which can be fatal, especially when combined with benzodiazepines, alcohol, or other CNS depressants.
- Repeated use may lead to tolerance, physical dependence, and potential for addiction — risk factors include personal or family history of substance abuse.
- Hydromorphone should not be used during pregnancy or breastfeeding unless specifically directed by a physician due to risks of neonatal withdrawal syndrome.
What Is Hydromorphone Kalceks and What Is It Used For?
Hydromorphone Kalceks is a potent opioid pain-relieving injection containing hydromorphone hydrochloride. It is used to treat severe pain in adults and adolescents over 12 years when other analgesics have proven inadequate.
Hydromorphone belongs to the opioid class of analgesics, which act on specific receptors (mu-opioid receptors) in the brain and spinal cord to block pain signals. It is a semi-synthetic derivative of morphine and was first synthesised in the 1920s. Hydromorphone is classified as a strong opioid under the World Health Organization (WHO) analgesic ladder, placing it in the third step alongside morphine and fentanyl for managing moderate-to-severe pain that does not respond to weaker analgesics or non-opioid treatments.
Hydromorphone Kalceks is manufactured by AS KALCEKS, a pharmaceutical company based in Riga, Latvia. The product is approved throughout the European Economic Area (EEA) and is marketed under various names in different countries, including Austria, Denmark, Estonia, Finland, Germany, Ireland, Latvia, the Netherlands, Norway, and Sweden. It is available as a clear, colourless to slightly yellowish solution supplied in amber glass ampoules.
The medication is indicated for the treatment of severe pain in clinical settings. Common situations where hydromorphone may be prescribed include post-operative pain management, cancer-related pain (particularly when morphine is not tolerated or insufficient), trauma-related pain in hospital emergency departments, and pain associated with palliative and end-of-life care. It is not intended as a first-line analgesic and should only be initiated when non-opioid analgesics and weak opioids have failed to provide adequate relief.
Hydromorphone is available in four concentrations: 2 mg/ml, 10 mg/ml, 20 mg/ml, and 50 mg/ml. The higher concentrations (10, 20, and 50 mg/ml) are reserved for patients who have already developed tolerance to lower doses during long-term opioid therapy. Treatment must never be initiated with these higher-strength formulations. The 2 mg/ml concentration is the standard starting strength for opioid-naïve patients.
Important: Hydromorphone Kalceks is administered by healthcare professionals in clinical settings. It is not a self-administered medication. Your doctor will determine the appropriate dose based on the severity of your pain, your previous opioid exposure, age, and overall medical condition.
What Should You Know Before Taking Hydromorphone Kalceks?
Hydromorphone has strict contraindications and requires careful assessment of your medical history before use. Inform your doctor about all health conditions, medications, and any history of substance use disorder.
Contraindications
There are several situations in which hydromorphone must not be used. Your healthcare provider will assess these before starting treatment. Do not use Hydromorphone Kalceks if you:
- Are allergic to hydromorphone hydrochloride or any of the other ingredients (citric acid, sodium citrate, sodium chloride, sodium hydroxide, hydrochloric acid, water for injections)
- Have respiratory depression (abnormally slow or shallow breathing)
- Have severe chronic obstructive pulmonary disease (COPD) with significant airway obstruction
- Have cor pulmonale (heart problems resulting from chronic lung disease)
- Have acute abdominal pain of unknown cause (acute abdomen)
- Have paralytic ileus (a condition where the bowel stops functioning)
- Are taking monoamine oxidase inhibitors (MAOIs) such as tranylcypromine, phenelzine, isocarboxazid, moclobemide, or linezolid, or have taken them within the last 14 days
- Are in a coma
Warnings and Precautions
Before treatment with Hydromorphone Kalceks, inform your doctor if you have any of the following conditions, as special monitoring or dose adjustments may be necessary:
- Head injury: Hydromorphone can increase intracranial pressure and may mask neurological signs
- Seizure disorders: Opioids can lower the seizure threshold
- Alcohol dependence or history of substance abuse: Increased risk of developing opioid dependence
- Psychiatric conditions: Including depression, anxiety, personality disorders, or toxic psychosis
- Hypotension with hypovolaemia: Low blood pressure associated with low blood volume
- Gallbladder disease: Opioids can cause biliary spasm
- Pancreatitis: Opioids can exacerbate pancreatic inflammation
- Inflammatory or obstructive bowel disease: Opioids slow gut motility
- Prostatic hypertrophy: May cause urinary retention
- Adrenal insufficiency (e.g. Addison’s disease): Risk of adrenal crisis
- Hypothyroidism: May increase sensitivity to respiratory depressant effects
- Chronic obstructive pulmonary disease (COPD) or reduced respiratory function: Increased vulnerability to respiratory depression
- Elderly, debilitated, or frail patients: Enhanced sensitivity to opioid effects
- Severe renal impairment: Hydromorphone metabolites may accumulate
- Severe hepatic impairment: Altered drug metabolism
Critical Warning — Respiratory Depression: The most serious risk of opioid use is respiratory depression (dangerously slow, shallow breathing). This risk is highest at the start of treatment, after dose increases, in elderly or debilitated patients, and when hydromorphone is used with other central nervous system depressants. Respiratory depression can be fatal if not recognised and treated promptly.
Tolerance, Dependence, and Addiction
Hydromorphone is a controlled substance with recognised potential for tolerance, dependence, and addiction. Repeated use may lead to the body requiring progressively higher doses to achieve the same analgesic effect (tolerance). Physical dependence can develop, meaning that abrupt discontinuation may cause withdrawal symptoms including restlessness, anxiety, insomnia, muscle twitching, tremors, and gastrointestinal disturbances.
Certain individuals are at greater risk of developing opioid dependence or addiction. Risk factors include a personal or family history of alcohol, prescription drug, or illicit substance abuse; smoking; and a history of mood disorders such as depression, anxiety, or personality disorders. If you notice signs of dependence — such as needing the medication for longer than prescribed, using higher doses than recommended, difficulty controlling use, or using the medication for reasons other than pain relief — speak with your doctor immediately.
When discontinuing hydromorphone after prolonged use, your doctor will gradually taper the dose to prevent withdrawal symptoms. Never stop the medication abruptly without medical guidance.
Sleep-Disordered Breathing
Hydromorphone can cause sleep-disordered breathing, including central sleep apnoea (pauses in breathing during sleep) and sleep-related hypoxaemia (low blood oxygen levels during sleep). Symptoms may include observed breathing pauses during sleep, nocturnal awakenings with shortness of breath, difficulty maintaining sleep, and excessive daytime sleepiness. If you or someone around you notices these symptoms, contact your doctor, who may consider reducing the dose.
Pregnancy and Breastfeeding
Hydromorphone crosses the placenta and should not be used during pregnancy unless your doctor has specifically determined that the benefits outweigh the risks. Use during labour may impair uterine contractions and cause respiratory depression in the newborn. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome (NOWS) in the infant, characterised by high-pitched crying, irritability, seizures, poor feeding, and diarrhoea.
Hydromorphone is excreted in breast milk and should not be used during breastfeeding, as it may cause sedation and respiratory depression in the nursing infant.
Driving and Operating Machinery
Hydromorphone can cause drowsiness, dizziness, and blurred vision, all of which impair the ability to drive or operate machinery safely. This is particularly significant at the start of treatment, after dose changes, when switching from another opioid, or when alcohol or other CNS-active medications are used concurrently. Do not drive or operate hazardous machinery until you know how hydromorphone affects you. Follow your doctor’s specific advice regarding these activities.
How Does Hydromorphone Kalceks Interact with Other Drugs?
Hydromorphone has significant interactions with many commonly used medications. The most dangerous combinations involve other CNS depressants, which can cause life-threatening respiratory depression, profound sedation, and coma.
Always inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements. Some combinations can result in serious, potentially fatal interactions.
Major Interactions (Life-Threatening or Contraindicated)
| Drug / Class | Effect | Recommendation |
|---|---|---|
| MAO inhibitors (tranylcypromine, phenelzine, isocarboxazid, moclobemide, linezolid) | Risk of serotonin syndrome, severe respiratory depression, hypotension, coma | Contraindicated. Do not use within 14 days of MAOIs. |
| Benzodiazepines (diazepam, lorazepam, midazolam, alprazolam) | Profound sedation, respiratory depression, coma, death | Avoid combination when possible. If necessary, use lowest effective doses with limited duration. |
| Gabapentin & Pregabalin | Increased risk of opioid overdose, respiratory depression, death | Use with extreme caution. Monitor closely for signs of respiratory depression. |
| Other opioid analgesics | Additive respiratory depression, sedation, overdose risk | Careful dose adjustment required. Monitor respiratory function. |
| Alcohol | Enhanced CNS depression, respiratory depression, hypotension | Avoid alcohol completely during treatment. |
Moderate Interactions
| Drug / Class | Effect | Recommendation |
|---|---|---|
| Sedating antihistamines (diphenhydramine, chlorphenamine, hydroxyzine) | Increased drowsiness, sedation, and respiratory depression | Monitor for excessive sedation. Consider non-sedating alternatives. |
| Antipsychotics / Neuroleptics (haloperidol, quetiapine, olanzapine) | Enhanced sedation, hypotension, respiratory depression | Use lowest effective doses. Monitor vital signs. |
| Antidepressants (SSRIs, SNRIs, tricyclics) | Increased sedation; risk of serotonin syndrome with some agents | Monitor for signs of serotonin syndrome and excessive sedation. |
| Barbiturates (phenobarbital) | Additive CNS and respiratory depression | Avoid combination where possible. Reduce doses if concurrent use necessary. |
| Muscle relaxants (baclofen, tizanidine) | Increased sedation and respiratory depression | Monitor closely. Consider dose reduction of one or both agents. |
| Anti-Parkinson agents | May enhance sedative effects; opioids can worsen constipation | Monitor for increased sedation and constipation. |
| Antiemetics (metoclopramide, ondansetron) | May alter gut motility; potential pharmacodynamic interactions | Generally safe to co-administer but monitor for effectiveness. |
Important: If you are scheduled for surgery, inform the anaesthetic team that you are receiving hydromorphone, as they may need to adjust anaesthetic dosing. Mixed agonist-antagonist opioids (such as buprenorphine, nalbuphine, and pentazocine) should be used with caution, as they may reduce the analgesic effect of hydromorphone or precipitate withdrawal symptoms.
What Is the Correct Dosage of Hydromorphone Kalceks?
Hydromorphone Kalceks dosing is individualised by a healthcare professional based on pain severity, prior opioid exposure, age, and weight. It is administered via intravenous or subcutaneous injection or infusion in clinical settings only.
The dosage of Hydromorphone Kalceks must be determined by a physician experienced in the management of severe pain with opioid analgesics. The principle of opioid therapy is to titrate the dose upward until adequate pain relief is achieved with acceptable side effects. The following are general dosing guidelines; actual doses may vary significantly between patients.
Adults and Adolescents (Over 12 Years)
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| IV bolus | 1–1.5 mg | Every 3–4 hours | Administer slowly over 2–3 minutes |
| SC injection | 1–2 mg | Every 3–4 hours | Single injection into subcutaneous tissue |
| IV or SC infusion | 0.15–0.45 mg/hour | Continuous | Or 0.004 mg/kg/hour based on body weight |
| PCA (patient-controlled analgesia) | 0.2 mg bolus | Lockout: 5–10 min | Patient-activated with a safety lockout interval |
Children (Under 12 Years)
Not Recommended
Hydromorphone Kalceks is not recommended for use in children under 12 years of age due to insufficient data on safety and efficacy in this age group.
Elderly Patients (Over 75 Years)
Dose Reduction Required
Elderly patients are more sensitive to the effects of opioids, particularly respiratory depression, sedation, and hypotension. Lower starting doses are recommended, and titration should be more gradual. Your doctor will carefully adjust the dose based on clinical response and tolerance.
Renal and Hepatic Impairment
Dose Adjustment Needed
Patients with significant kidney or liver problems may require lower doses of hydromorphone. Renal impairment can lead to accumulation of the active metabolite hydromorphone-3-glucuronide (H3G), which may cause neuroexcitatory effects. Hepatic impairment can reduce the drug’s metabolism, leading to higher plasma levels and prolonged effects. Your physician will adjust the dose and monitor you carefully.
Higher Strength Formulations (10, 20, 50 mg/ml)
The higher concentration formulations are intended exclusively for patients who have already been established on long-term opioid therapy and no longer achieve adequate pain relief with lower-dose hydromorphone preparations (2 mg/ml) or opioid analgesics of comparable potency. Opioid treatment must never be initiated with the 10, 20, or 50 mg/ml strengths, as this could lead to fatal overdose in opioid-naïve patients.
Missed Dose
If a scheduled dose is missed, administer it as soon as the omission is noticed. Never administer a double dose to compensate for a missed one. If you miss a dose or receive a lower dose than prescribed, you may experience inadequate or insufficient pain relief. Inform your healthcare provider so the dosing schedule can be adjusted.
Overdose
Overdose Emergency: In case of suspected hydromorphone overdose, seek emergency medical assistance immediately. Symptoms include pinpoint pupils, severe respiratory depression (very slow, shallow, or stopped breathing), hypotension (dangerously low blood pressure), bradycardia (slow heart rate), loss of consciousness progressing to coma, and aspiration pneumonia. Naloxone is the specific antidote and should be administered as soon as possible. In severe cases, an overdose can be fatal.
If you suspect an overdose, do not attempt to engage in any activity requiring alertness (such as driving). Seek emergency care and bring the medication packaging to show healthcare providers.
What Are the Side Effects of Hydromorphone Kalceks?
Like all opioid medications, hydromorphone can cause side effects. The most common include drowsiness, dizziness, constipation, nausea, and vomiting. The most serious risk is respiratory depression. Not everyone experiences these effects.
Side effects of hydromorphone are generally dose-related and reflect its pharmacological action on opioid receptors throughout the body. Many side effects, particularly nausea and drowsiness, tend to diminish as tolerance develops over the first few days of treatment. Constipation, however, typically persists throughout therapy and may require prophylactic laxative use.
Seek immediate medical attention if you experience signs of a serious allergic reaction (anaphylaxis): sudden wheezing, difficulty breathing, swelling of eyelids, face, lips, mouth, or throat, or widespread rash with itching. Also seek emergency help for severe breathing difficulties, extreme drowsiness from which you cannot be roused, or bluish discolouration of the lips or fingernails.
Very Common
Affects more than 1 in 10 people
- Dizziness
- Increased drowsiness / somnolence
- Constipation
- Nausea
- Vomiting
- Pruritus (itching)
- Asthenia (feeling weaker than usual)
Common
Affects up to 1 in 10 people
- Confusion
- Anxiety and insomnia
- Hallucinations
- Loss of appetite
- Hypotension (low blood pressure)
- Dry mouth
- Abdominal pain or discomfort
- Excessive sweating (hyperhidrosis)
- Rash
- Difficulty urinating, urinary urgency
- Injection site reactions
Uncommon
Affects up to 1 in 100 people
- Dysphoria (feeling of unease) or euphoria
- Headache, tremor, muscle twitching
- Paraesthesia (tingling in hands or feet)
- Miosis (constricted pupils), blurred vision
- Tachycardia (rapid heartbeat)
- Dyspepsia (indigestion)
- Diarrhoea, taste disturbances
- Urticaria (itchy rash / hives)
- Decreased libido, erectile dysfunction
- Drug tolerance
- Withdrawal symptoms (with dose reduction)
- Depression, nightmares
- Dyspnoea (shortness of breath)
- Abnormal liver function tests
Rare
Affects up to 1 in 1,000 people
- Drug dependence, restlessness
- Seizures or convulsions
- Excessive sedation
- Bradycardia (slow heart rate)
- Cardiac arrhythmia (irregular heartbeat)
- Respiratory depression or bronchospasm
- Facial flushing
- Abnormal pancreatic enzyme tests
Very Rare
Affects up to 1 in 10,000 people
- Opioid-induced hyperalgesia (increased pain sensitivity despite treatment)
- Paralytic ileus (bowel obstruction due to loss of peristalsis)
- Peripheral oedema (swelling of hands, ankles, or feet)
- Injection site induration (hardening of skin at injection site, particularly with repeated subcutaneous use)
- Aggression
Frequency not known: Hot flushes, neonatal withdrawal symptoms (in newborns of mothers who used hydromorphone during pregnancy), sleep apnoea (pauses in breathing during sleep).
Managing common side effects: Constipation is almost universal with opioid use. Your doctor may prescribe laxatives prophylactically. Increasing dietary fibre (fruits, vegetables, wholegrains) and fluid intake can help. Nausea and vomiting usually subside within the first few days but can be managed with antiemetic medication if persistent.
How Should You Store Hydromorphone Kalceks?
Hydromorphone Kalceks should be stored in the original packaging, protected from light, and must not be frozen. No special temperature requirements apply. After opening, use immediately.
Store this medication out of the sight and reach of children. As a controlled substance, hydromorphone should be stored securely in accordance with local regulations to prevent diversion and misuse.
- Temperature: No special temperature storage requirements. Store at room temperature.
- Light protection: Keep ampoules in the outer carton to protect from light, as the solution is light-sensitive.
- Freezing: Do not freeze.
- After opening: Use immediately. The ampoules are for single use only — discard any remaining solution after use.
- After dilution: Chemical and physical stability has been demonstrated for 7 days at both 25°C and 2–8°C. From a microbiological standpoint, the diluted product should be used immediately. If not used immediately, in-use storage should not normally exceed 24 hours at 2–8°C unless dilution was performed under controlled and validated aseptic conditions.
- Visual inspection: Always inspect the solution before use. Only clear solutions free from visible particles should be used.
- Expiry date: Do not use after the expiry date printed on the label and carton (EXP). The expiry date refers to the last day of the stated month.
Do not dispose of medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. As a controlled substance, special disposal procedures may apply in your jurisdiction.
What Does Hydromorphone Kalceks Contain?
Hydromorphone Kalceks contains hydromorphone hydrochloride as the active substance, with citric acid, sodium citrate, sodium chloride, and water for injections as excipients.
Active Ingredient
| Strength | Hydromorphone HCl per 1 ml | Equivalent Hydromorphone Base |
|---|---|---|
| 2 mg/ml | 2 mg | 1.77 mg |
| 10 mg/ml | 10 mg (1 ml) or 100 mg (10 ml) | 8.87 mg per ml |
| 20 mg/ml | 20 mg | 17.73 mg |
| 50 mg/ml | 50 mg | 44.33 mg |
Other Ingredients (Excipients)
- Citric acid (buffering agent)
- Sodium citrate (buffering agent)
- Sodium chloride (tonicity agent)
- Sodium hydroxide (pH adjustment)
- Concentrated hydrochloric acid (pH adjustment)
- Water for injections (solvent)
Sodium content: This medicine contains less than 1 mmol (23 mg) sodium per ml and is therefore essentially sodium-free.
Appearance and Packaging
Hydromorphone Kalceks is a clear, colourless to slightly yellowish solution for injection or infusion, free from visible particles. It is supplied in amber glass ampoules of 1 ml or 10 ml (10 ml ampoules available for the 10 mg/ml strength only). Pack sizes are 5 or 10 ampoules. Each ampoule is marked with a colour-coded ring corresponding to its strength and volume. Not all pack sizes may be marketed in all countries.
Compatibility Information (Healthcare Professionals)
Hydromorphone Kalceks — whether undiluted or diluted with sodium chloride 9 mg/ml (0.9%) solution, glucose 50 mg/ml (5%) solution, or water for injections — is physically and chemically compatible with polypropylene syringes, polyethylene or PVC tubing, and PVC or EVA infusion bags.
The solution is also compatible with: hyoscine butylbromide, hyoscine hydrobromide, dexamethasone sodium phosphate, haloperidol, midazolam hydrochloride, metoclopramide hydrochloride, levomepromazine hydrochloride, glycopyrronium bromide, and ketamine hydrochloride. It must not be mixed with other medications beyond those listed.
The solution pH is 3.5–4.5 and the osmolality is approximately 280 mOsm/kg.
Frequently Asked Questions
Hydromorphone Kalceks is a strong opioid analgesic used for the treatment of severe pain in adults and adolescents over 12 years of age. It is administered by healthcare professionals via intravenous or subcutaneous injection or infusion, typically in hospital or clinical settings such as post-operative care, cancer pain management, or palliative care. It is approximately 5–10 times more potent than morphine.
Very common side effects (affecting more than 1 in 10 people) include dizziness, drowsiness, constipation, nausea, vomiting, itching, and feeling weaker than usual. Most of these are dose-related and may diminish as your body adjusts. Constipation typically persists throughout treatment and may require laxatives. Your healthcare provider can prescribe antiemetics for nausea if needed.
Yes, hydromorphone is approximately 5–10 times more potent than morphine on a milligram-for-milligram basis when given parenterally (by injection). This higher potency means smaller volumes are needed, which can be particularly advantageous for subcutaneous infusion where volume matters. However, potency and efficacy are different concepts — both drugs can achieve equivalent pain relief when dosed appropriately.
Hydromorphone, like all opioids, has a recognised potential for dependence and addiction. Risk factors include personal or family history of substance abuse, smoking, and psychiatric conditions such as depression or anxiety. When used as prescribed under medical supervision for legitimate pain, the risk is lower, but it is never zero. Your doctor should regularly reassess the ongoing need for opioid therapy and watch for signs of misuse.
A hydromorphone overdose is a medical emergency. Call your local emergency number immediately. Signs include pinpoint pupils, extremely slow or absent breathing, severe drowsiness or unresponsiveness, low blood pressure, and coma. Naloxone (Narcan) is the specific antidote and should be administered as quickly as possible. Place the person in the recovery position if unconscious but breathing, and do not leave them unattended.
Hydromorphone should generally be avoided during pregnancy unless the prescribing physician determines it is strictly necessary. The drug crosses the placenta. Prolonged use during pregnancy can lead to neonatal opioid withdrawal syndrome (NOWS) in the newborn, with symptoms including high-pitched crying, irritability, seizures, poor feeding, and diarrhoea. During labour, it may weaken contractions and cause respiratory depression in the newborn. Hydromorphone is also excreted in breast milk and should not be used during breastfeeding.
References
- European Medicines Agency (EMA). Summary of Product Characteristics — Hydromorphone Kalceks. EMA/CHMP. Available at: www.ema.europa.eu.
- World Health Organization (WHO). WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. Geneva: WHO; 2018. Available at: www.who.int.
- National Institute for Health and Care Excellence (NICE). Palliative care for adults: strong opioids for pain relief. Clinical guideline [CG140]. Updated 2020. Available at: www.nice.org.uk.
- Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews. 2002;(1):CD003447. doi: 10.1002/14651858.CD003447.
- Felden L, Walter C, Harder S, et al. Comparative clinical effects of hydromorphone and morphine: a meta-analysis. British Journal of Anaesthesia. 2011;107(3):319–328. doi: 10.1093/bja/aer232.
- British National Formulary (BNF). Hydromorphone hydrochloride. Available at: bnf.nice.org.uk.
- US Food and Drug Administration (FDA). Hydromorphone Hydrochloride Injection — Prescribing Information. Available at: www.fda.gov.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: WHO; 2023.
- Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncology. 2012;13(2):e58–e68. doi: 10.1016/S1470-2045(12)70040-2.
- Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022. MMWR Recomm Rep. 2022;71(No. RR-3):1–95. doi: 10.15585/mmwr.rr7103a1.
Editorial Team
This article has been written by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in pain medicine, anaesthesiology, palliative care, and clinical pharmacology. All content is reviewed according to international medical guidelines (WHO, EMA, NICE, FDA) and follows the GRADE evidence framework.
Our editorial process includes systematic literature review, fact-checking against primary sources, peer review by independent medical experts, and regular updates to reflect the latest evidence. iMedic receives no commercial funding and has no conflicts of interest with pharmaceutical companies.